Phase III study with FOLFIRI plus cetuximab versus FOLFIRI plus cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC

Carmine Pinto, Nicola Normanno, Armando Orlandi, Francesca Fenizia, Angela Damato, Evaristo Maiello, Emiliano Tamburini, Francesco Di Costanzo, Giuseppe Tonini, Domenico Bilancia, Domenico Corsi, Salvatore Pisconti, Francesco Ferrau, Stefania Gori, Bruno Daniele, Alberto Zaniboni, Hector Soto Parra, Giovanni Luca Frassinetti, Rosario Vincenzo Iaffaioli, Antonio CassataMaria Giulia Zampino, Lazzaro Repetto, Maria Alessandra Calegari, Carlo Barone

Research output: Contribution to journalArticle

Abstract

The optimal duration and intensity of first-line therapy in metastatic colorectal cancer patients once they have achieved an objective response is controversial. In a molecularly selected RAS and BRAF wild-type (wt) population, this concern is amplified. Once disease control has been achieved with a combination therapy including an anti-EGFR antibody, further exposure both to cytotoxic drugs and targeted therapy might result only in increased toxicity. In unresectable metastatic RAS and BRAF wt colorectal cancer patients, a deintensified therapy could represent a valuable option that might preserve quality of life. We designed a study to compare FOLFIRI/cetuximab to FOLFIRI/cetuximab for eight cycles followed by cetuximab alone in first-line treatment of RAS and BRAF (wt) metastatic colorectal cancer patients.
Original languageEnglish
Pages (from-to)1339-1346
Number of pages8
JournalFuture Oncology
Volume14
Issue number14
DOIs
Publication statusPublished - Jun 1 2018

Fingerprint

Colorectal Neoplasms
Therapeutics
Anti-Idiotypic Antibodies
Quality of Life
Drug Therapy
Cetuximab
Population

Keywords

  • cetuximab
  • colorectal cancer
  • de-escalation therapy
  • RAS and BRAF wild-type

Cite this

Phase III study with FOLFIRI plus cetuximab versus FOLFIRI plus cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC. / Pinto, Carmine; Normanno, Nicola; Orlandi, Armando; Fenizia, Francesca; Damato, Angela; Maiello, Evaristo; Tamburini, Emiliano; Di Costanzo, Francesco; Tonini, Giuseppe; Bilancia, Domenico; Corsi, Domenico; Pisconti, Salvatore; Ferrau, Francesco; Gori, Stefania; Daniele, Bruno; Zaniboni, Alberto; Parra, Hector Soto; Frassinetti, Giovanni Luca; Iaffaioli, Rosario Vincenzo; Cassata, Antonio; Zampino, Maria Giulia; Repetto, Lazzaro; Calegari, Maria Alessandra; Barone, Carlo.

In: Future Oncology, Vol. 14, No. 14, 01.06.2018, p. 1339-1346.

Research output: Contribution to journalArticle

Pinto, C, Normanno, N, Orlandi, A, Fenizia, F, Damato, A, Maiello, E, Tamburini, E, Di Costanzo, F, Tonini, G, Bilancia, D, Corsi, D, Pisconti, S, Ferrau, F, Gori, S, Daniele, B, Zaniboni, A, Parra, HS, Frassinetti, GL, Iaffaioli, RV, Cassata, A, Zampino, MG, Repetto, L, Calegari, MA & Barone, C 2018, 'Phase III study with FOLFIRI plus cetuximab versus FOLFIRI plus cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC', Future Oncology, vol. 14, no. 14, pp. 1339-1346. https://doi.org/10.2217/fon-2017-0592
Pinto, Carmine ; Normanno, Nicola ; Orlandi, Armando ; Fenizia, Francesca ; Damato, Angela ; Maiello, Evaristo ; Tamburini, Emiliano ; Di Costanzo, Francesco ; Tonini, Giuseppe ; Bilancia, Domenico ; Corsi, Domenico ; Pisconti, Salvatore ; Ferrau, Francesco ; Gori, Stefania ; Daniele, Bruno ; Zaniboni, Alberto ; Parra, Hector Soto ; Frassinetti, Giovanni Luca ; Iaffaioli, Rosario Vincenzo ; Cassata, Antonio ; Zampino, Maria Giulia ; Repetto, Lazzaro ; Calegari, Maria Alessandra ; Barone, Carlo. / Phase III study with FOLFIRI plus cetuximab versus FOLFIRI plus cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC. In: Future Oncology. 2018 ; Vol. 14, No. 14. pp. 1339-1346.
@article{d6663863f291408fb5f642735b15a8ed,
title = "Phase III study with FOLFIRI plus cetuximab versus FOLFIRI plus cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC",
abstract = "The optimal duration and intensity of first-line therapy in metastatic colorectal cancer patients once they have achieved an objective response is controversial. In a molecularly selected RAS and BRAF wild-type (wt) population, this concern is amplified. Once disease control has been achieved with a combination therapy including an anti-EGFR antibody, further exposure both to cytotoxic drugs and targeted therapy might result only in increased toxicity. In unresectable metastatic RAS and BRAF wt colorectal cancer patients, a deintensified therapy could represent a valuable option that might preserve quality of life. We designed a study to compare FOLFIRI/cetuximab to FOLFIRI/cetuximab for eight cycles followed by cetuximab alone in first-line treatment of RAS and BRAF (wt) metastatic colorectal cancer patients.",
keywords = "cetuximab, colorectal cancer, de-escalation therapy, RAS and BRAF wild-type",
author = "Carmine Pinto and Nicola Normanno and Armando Orlandi and Francesca Fenizia and Angela Damato and Evaristo Maiello and Emiliano Tamburini and {Di Costanzo}, Francesco and Giuseppe Tonini and Domenico Bilancia and Domenico Corsi and Salvatore Pisconti and Francesco Ferrau and Stefania Gori and Bruno Daniele and Alberto Zaniboni and Parra, {Hector Soto} and Frassinetti, {Giovanni Luca} and Iaffaioli, {Rosario Vincenzo} and Antonio Cassata and Zampino, {Maria Giulia} and Lazzaro Repetto and Calegari, {Maria Alessandra} and Carlo Barone",
year = "2018",
month = "6",
day = "1",
doi = "10.2217/fon-2017-0592",
language = "English",
volume = "14",
pages = "1339--1346",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "14",

}

TY - JOUR

T1 - Phase III study with FOLFIRI plus cetuximab versus FOLFIRI plus cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC

AU - Pinto, Carmine

AU - Normanno, Nicola

AU - Orlandi, Armando

AU - Fenizia, Francesca

AU - Damato, Angela

AU - Maiello, Evaristo

AU - Tamburini, Emiliano

AU - Di Costanzo, Francesco

AU - Tonini, Giuseppe

AU - Bilancia, Domenico

AU - Corsi, Domenico

AU - Pisconti, Salvatore

AU - Ferrau, Francesco

AU - Gori, Stefania

AU - Daniele, Bruno

AU - Zaniboni, Alberto

AU - Parra, Hector Soto

AU - Frassinetti, Giovanni Luca

AU - Iaffaioli, Rosario Vincenzo

AU - Cassata, Antonio

AU - Zampino, Maria Giulia

AU - Repetto, Lazzaro

AU - Calegari, Maria Alessandra

AU - Barone, Carlo

PY - 2018/6/1

Y1 - 2018/6/1

N2 - The optimal duration and intensity of first-line therapy in metastatic colorectal cancer patients once they have achieved an objective response is controversial. In a molecularly selected RAS and BRAF wild-type (wt) population, this concern is amplified. Once disease control has been achieved with a combination therapy including an anti-EGFR antibody, further exposure both to cytotoxic drugs and targeted therapy might result only in increased toxicity. In unresectable metastatic RAS and BRAF wt colorectal cancer patients, a deintensified therapy could represent a valuable option that might preserve quality of life. We designed a study to compare FOLFIRI/cetuximab to FOLFIRI/cetuximab for eight cycles followed by cetuximab alone in first-line treatment of RAS and BRAF (wt) metastatic colorectal cancer patients.

AB - The optimal duration and intensity of first-line therapy in metastatic colorectal cancer patients once they have achieved an objective response is controversial. In a molecularly selected RAS and BRAF wild-type (wt) population, this concern is amplified. Once disease control has been achieved with a combination therapy including an anti-EGFR antibody, further exposure both to cytotoxic drugs and targeted therapy might result only in increased toxicity. In unresectable metastatic RAS and BRAF wt colorectal cancer patients, a deintensified therapy could represent a valuable option that might preserve quality of life. We designed a study to compare FOLFIRI/cetuximab to FOLFIRI/cetuximab for eight cycles followed by cetuximab alone in first-line treatment of RAS and BRAF (wt) metastatic colorectal cancer patients.

KW - cetuximab

KW - colorectal cancer

KW - de-escalation therapy

KW - RAS and BRAF wild-type

U2 - 10.2217/fon-2017-0592

DO - 10.2217/fon-2017-0592

M3 - Article

VL - 14

SP - 1339

EP - 1346

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 14

ER -